Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

Abroad (travel likely)RecruitingPHASE3

Conditions

Pancreatic Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Ying Yang, MD) · yangying@fudanpci.org · 86 21 64175590
Contact: Principal Investigator (Guopei Luo, MD)

Study leads

Guopei Luo, MD
Principal Investigator
Fudan University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Metastatic Pancreatic Adenocarcinoma · Locally Advanced Pancreatic Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Charleston, United States · Charleston, United States

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

Pancreatic Adenocarcinoma · Metastatic Pancreatic Cancer · Basal Cell Neoplasm

Abroad (travel likely)RecruitingPHASE1, PHASE2

Chapel Hill, United States

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Ductal Adenocarcinoma · Resectable Pancreatic Adenocarcinoma · Stage I Pancreatic Cancer AJCC v8

Abroad (travel likely)RecruitingPHASE2

Atlanta, United States

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Cancer · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma

Abroad (travel likely)RecruitingPHASE3

Los Angeles, United States · Los Angeles, United States